NEMUS Bioscience announced the company will present new data of NB2111 analgesic and anti-addiction.
NEMUS Bioscience (OTCQB:NMUS) announced the company will present new data on NB2111 analgesic and anti-addiction cannabinoid treatment.
As quoted in the press release:
The data will be presented by Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the University of Mississippi School of Pharmacy and co-inventor of the CBD analogue, NB2111. The title of the presentation is: “Differential Modulation of Addiction and Pain by Cannabidiol (CBD) and CBD Derivatives.”
The data being presented will review the physiology of plant-derived CBD followed by the therapeutic activity associated with the bio-engineered analogue of CBD in multiple animal studies. The proprietary molecule was discovered at the University and Elsohly Laboratories, Inc. (ELI). Findings from the animal studies point to the superiority of the Nemus proprietary analogue of CBD, NB2111, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator. Additionally, NB2111 displayed abuse-deterrent activity in a validated animal model of oxycontin addiction. The in vivo research studying the analgesia and anti-addiction profile of NB2111 was led by Dr. Kenneth Sufka professor of psychology and pharmacology at the University of Mississippi, who will also be presenting data from these studies at the Society of Neuroscience meeting in the fall.